14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $5.34 $19.02 Tuesday, 7th May 2024 MGNX stock ended at $16.05. This is 1.95% less than the trading day before Monday, 6th May 2024. During the day the stock fluctuated 4.80% from a day low at $15.62 to a day high of $16.37.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical MacroGenics prices

Date Open High Low Close Volume
Dec 29, 2016 $19.83 $20.38 $19.70 $20.07 290 569
Dec 28, 2016 $19.45 $20.12 $19.14 $19.81 279 892
Dec 27, 2016 $19.71 $20.18 $19.22 $19.40 197 789
Dec 23, 2016 $18.43 $19.65 $18.43 $19.57 448 524
Dec 22, 2016 $18.97 $18.97 $18.22 $18.36 377 367
Dec 21, 2016 $19.80 $19.92 $18.82 $18.91 239 092
Dec 20, 2016 $20.47 $20.92 $19.70 $19.90 222 780
Dec 19, 2016 $20.10 $20.69 $19.65 $19.81 249 260
Dec 16, 2016 $19.68 $20.75 $19.56 $20.26 559 144
Dec 15, 2016 $20.05 $20.10 $19.22 $19.65 810 274
Dec 14, 2016 $23.18 $23.47 $19.67 $19.81 1 226 284
Dec 13, 2016 $25.78 $26.12 $23.34 $23.42 498 034
Dec 12, 2016 $26.80 $27.00 $25.36 $25.46 292 284
Dec 09, 2016 $27.60 $28.48 $26.94 $27.15 219 618
Dec 08, 2016 $26.33 $27.28 $25.14 $27.22 224 198
Dec 07, 2016 $27.79 $28.48 $25.95 $26.47 204 523
Dec 06, 2016 $27.16 $28.35 $26.43 $28.24 268 122
Dec 05, 2016 $26.71 $27.77 $25.94 $27.08 272 754
Dec 02, 2016 $24.22 $26.75 $23.85 $26.27 273 823
Dec 01, 2016 $26.07 $26.24 $24.07 $24.31 262 489
Nov 30, 2016 $27.64 $28.05 $25.75 $25.93 197 278
Nov 29, 2016 $27.49 $27.83 $26.76 $27.48 147 534
Nov 28, 2016 $27.99 $27.99 $26.46 $27.31 233 404
Nov 25, 2016 $28.00 $28.90 $26.97 $28.13 105 601
Nov 23, 2016 $26.48 $28.07 $25.98 $27.91 394 583
Click to get the best stock tips daily for free!

About MacroGenics

MacroGenics MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The... MGNX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT